Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA - The Lancet thelancet.com Submitted by thelancet4803 on June 26, 2023 at 10:04 PM in health No comments 40